1996
Disruption of CD40–CD40 Ligand Interactions Results in an Enhanced Susceptibility to Leishmania amazonensis Infection
Soong L, Xu J, Grewal I, Kima P, Sun J, Longley B, Ruddle N, McMahon-Pratt D, Flavell R. Disruption of CD40–CD40 Ligand Interactions Results in an Enhanced Susceptibility to Leishmania amazonensis Infection. Immunity 1996, 4: 263-273. PMID: 8624816, DOI: 10.1016/s1074-7613(00)80434-3.Peer-Reviewed Original ResearchConceptsCD40L-/- miceImmune responseCD40-CD40 ligand interactionCD40L knockout miceLeishmania amazonensis infectionProgressive ulcerative lesionTissue parasite burdenCD40-CD40L interactionCellular immune responsesProtective immune responseWild-type miceHost immune responseImpaired T cellNitric oxide productionAmazonensis infectionUlcerative lesionsInflammatory responseNecrosis factorCD40 ligandT cellsIFN-gammaKnockout miceMacrophage activationParasite burdenOxide production
1995
Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis
Soong L, Duboise S, Kima P, McMahon-Pratt D. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infection And Immunity 1995, 63: 3559-3566. PMID: 7642292, PMCID: PMC173494, DOI: 10.1128/iai.63.9.3559-3566.1995.Peer-Reviewed Original ResearchConceptsBALB/c miceAmastigote antigensC miceImmune responseTh1 cell-mediated immune responseCell-mediated immune responsesCBA/J miceCross-species protectionGamma interferon productionWeeks of infectionAmastigotes of LeishmaniaHost immune responseStage-specific antigensAmazonensis infectionImmunized miceIntraperitoneal injectionJ miceCorynebacterium parvumLeishmaniasis vaccineProliferative responseVaccine potentialCutaneous leishmaniasisParasite burdenInterferon productionAntigen
1991
Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease.
Barral A, Pedral-Sampaio D, Grimaldi G, Momen H, McMahon-Pratt D, de Jesus A, Almeida R, Badaro R, Barral-Netto M, Carvalho E, Johnson W. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. American Journal Of Tropical Medicine And Hygiene 1991, 44: 536-46. PMID: 2063957, DOI: 10.4269/ajtmh.1991.44.536.Peer-Reviewed Original ResearchConceptsMucocutaneous leishmaniasisCutaneous leishmaniasisClinical presentationVisceral leishmaniasisCases of CLMonoclonal antibodiesLeishmania amazonensisCases of DCLL. amazonensis infectionDifferent clinical presentationsDifferent clinical formsDifferent Leishmania speciesAmazonensis infectionClinical groundsIndistinguishable clinical presentationDermal leishmaniasisSpecific monoclonal antibodiesClinical formsClinical diseaseLeishmanial diseaseL. chagasiWide spectrumLeishmania referenceLeishmaniasisL. amazonensis
1988
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infection And Immunity 1988, 56: 3272-3279. PMID: 3182080, PMCID: PMC259734, DOI: 10.1128/iai.56.12.3272-3279.1988.Peer-Reviewed Original ResearchConceptsMouse strainsComplete protectionBALB/c strainLeishmania amazonensis infectionT cell immunityProtective immune responseOnset of infectionC. parvumAmazonensis infectionInfecting doseProtective immunityChallenge infectionC57BL/6 miceAntibody responseCBA miceComplete adjuvantEffective adjuvantImmune responseImmunized animalsLog phase promastigotesLevel of protectionL. amazonensisInfectionC strainLeishmania amazonensis